Bionano Genomics, Inc.BNGO
| Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
---|
Cash and cash equivalents | 17 | 17 | 38 | 25 | 5 | 18 |
---|
Investments | - | - | - | 226 | 108 | 49 |
---|
Accounts receivable, net | 5 | 6 | 3 | 5 | 7 | 9 |
---|
Inventory | 1 | 3 | 3 | 12 | 30 | - |
---|
Inventory | - | - | - | - | - | 23 |
---|
Prepaid expenses and other current assets | 919,500 | 1 | 2 | 4 | 7 | 6 |
---|
Total current assets | 23 | 28 | 47 | 272 | 157 | 140 |
---|
Restricted investments | - | - | - | - | - | 35 |
---|
Total current assets | 23 | 28 | 47 | 272 | 157 | 140 |
---|
Restricted cash | - | - | - | - | 0 | 0 |
---|
Property and equipment, net | 2 | 2 | 5 | 10 | 18 | 23 |
---|
Operating lease right-of-use assets | - | - | - | 7 | 7 | 6 |
---|
Finance lease right-of-use assets | - | - | - | 4 | 4 | 4 |
---|
Intangible assets, net | - | - | 1 | 27 | 41 | 34 |
---|
Goodwill | - | - | 7 | 56 | 77 | - |
---|
Other long-term assets | - | - | 102,640 | 1 | 2 | 7 |
---|
Total assets | 25 | 30 | 60 | 377 | 308 | 214 |
---|
Accounts payable | 1 | 3 | 3 | 10 | 13 | 10 |
---|
Accrued expenses | 3 | 3 | 6 | 10 | 11 | 8 |
---|
Contract liabilities | 270,998 | 357,492 | 415,504 | 1 | 1 | - |
---|
Contract liabilities | - | - | - | - | - | 1 |
---|
Operating lease liability | - | - | - | 1 | 2 | 2 |
---|
Finance lease liability | - | - | - | 0 | 0 | 0 |
---|
Contingent consideration | - | - | - | - | 9 | - |
---|
Total current liabilities | 5 | 26 | 9 | 22 | 36 | 100 |
---|
Purchase option liability (at fair value) | - | - | - | - | - | 9 |
---|
Convertible notes payable (at fair value) | - | - | - | - | - | 70 |
---|
Total current liabilities | 5 | 26 | 9 | 22 | 36 | 100 |
---|
Operating Lease, Liability, Noncurrent | - | - | - | 5 | 6 | 4 |
---|
Finance Lease, Liability, Noncurrent | - | - | - | 4 | 4 | 4 |
---|
Contingent consideration, net of current portion | - | - | - | - | 13 | 11 |
---|
Deferred Revenue, Noncurrent | 304,467 | 182,648 | 97,875 | 0 | 0 | - |
---|
Long-term contract liabilities | - | - | - | - | - | 0 |
---|
Total liabilities | 15 | 27 | 25 | 40 | 58 | 118 |
---|
Preferred Stock, Value, Issued | - | - | - | - | - | - |
---|
Common Stock, Value, Issued | 1,004 | 3,427 | 18,995 | 0 | 0 | 0 |
---|
Additional paid-in capital | 83 | 106 | 179 | 554 | 599 | 677 |
---|
Accumulated deficit | -72,762,428 | -102,577,498 | -143,683,849 | -216 | -349 | -581 |
---|
Accumulated other comprehensive income (loss) | - | - | - | -1 | -1 | 0 |
---|
Total stockholders’ equity | 10 | 4 | 35 | 337 | 249 | 96 |
---|
Total liabilities and stockholders’ equity | 25 | 30 | 60 | 377 | 308 | 214 |
---|